I. Lax, W. H. Burgess, F. Bellot, A. Ullrich, J. Schlessinger et al., Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling., Molecular and Cellular Biology, vol.8, issue.4, pp.1831-1834, 1988.
DOI : 10.1128/MCB.8.4.1831

T. P. Garrett, N. M. Mckern, M. Lou, T. C. Elleman, T. E. Adams et al., Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor ??, Cell, vol.110, issue.6, pp.763-73, 2002.
DOI : 10.1016/S0092-8674(02)00940-6

N. E. Hynes and G. Macdonald, ErbB receptors and signaling pathways in cancer, Current Opinion in Cell Biology, vol.21, issue.2, pp.177-184, 2009.
DOI : 10.1016/j.ceb.2008.12.010

F. F. Barros, D. G. Powe, I. O. Ellis, and A. R. Green, Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments, Histopathology, vol.77, issue.4785, pp.560-572, 2010.
DOI : 10.1111/j.1365-2559.2010.03494.x

N. Normanno, M. R. Maiello, D. Luca, and A. , Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action?, Journal of Cellular Physiology, vol.95, issue.1, pp.13-19, 2003.
DOI : 10.1002/jcp.10194

Z. Suo, B. Risberg, M. G. Karlsson, K. Willman, A. Tierens et al., EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival, The Journal of Pathology, vol.63, issue.1, pp.17-25, 2002.
DOI : 10.1002/path.1003

Z. Wang, L. Zhang, T. K. Yeung, C. , and X. , Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation, Molecular Biology of the Cell, vol.10, issue.5, pp.1621-1636, 1999.
DOI : 10.1091/mbc.10.5.1621

X. Chen, T. K. Yeung, W. , and Z. , Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3, Biochemical and Biophysical Research Communications, vol.277, issue.3, pp.757-763, 2000.
DOI : 10.1006/bbrc.2000.3731

K. R. Schmitz, F. , and K. M. , Interaction of antibodies with ErbB receptor extracellular regions, Experimental Cell Research, vol.315, issue.4, pp.659-670, 2008.
DOI : 10.1016/j.yexcr.2008.10.008

G. Lurje and H. Lenz, EGFR Signaling and Drug Discovery, Oncology, vol.77, issue.6, pp.400-410, 2009.
DOI : 10.1159/000279388

N. E. Hynes, L. , and H. A. , ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005.
DOI : 10.1021/jm00130a020

M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge et al., A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnology, vol.50, issue.1, pp.127-132, 2008.
DOI : 10.1038/nbt1358

M. Harris, Monoclonal antibodies as therapeutic agents for cancer, The Lancet Oncology, vol.5, issue.5, pp.292-302, 2004.
DOI : 10.1016/S1470-2045(04)01467-6

M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, G. Fabris et al., Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies, Journal of Clinical Oncology, vol.22, issue.23, pp.4772-4778, 2004.
DOI : 10.1200/JCO.2004.00.117

K. Y. Chung, J. Shia, N. E. Kemeny, M. Shah, G. K. Schwartz et al., Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1810, 2005.
DOI : 10.1200/JCO.2005.08.037

N. S. Goldstein and M. Armin, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma, Cancer, vol.43, issue.5, pp.1331-1346, 2001.
DOI : 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M

F. Cappuzzo, V. Gregorc, E. Rossi, A. Cancellieri, E. Magrini et al., Gefitinib in Pretreated Non???Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC, Journal of Clinical Oncology, vol.21, issue.14, pp.2658-2663, 2003.
DOI : 10.1200/JCO.2003.01.039

D. Pas, T. Pelosi, G. De-braud, F. Veronesi, G. Curigliano et al., Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non???Small-Cell Lung Cancer Is Rare, Journal of Clinical Oncology, vol.22, issue.24, pp.4966-4970, 2004.
DOI : 10.1200/JCO.2004.01.195

I. H. Khan, J. Zhao, P. Ghosh, M. Ziman, C. Sweeney et al., Microbead Arrays for the Analysis of ErbB Receptor Tyrosine Kinase Activation and Dimerization in Breast Cancer Cells, ASSAY and Drug Development Technologies, vol.8, issue.1, pp.27-36, 2010.
DOI : 10.1089/adt.2009.0208

Y. Shi, W. Huang, Y. Tan, X. Jin, R. Dua et al., A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue, Diagnostic Molecular Pathology, vol.18, issue.1, pp.11-21, 2009.
DOI : 10.1097/PDM.0b013e31818cbdb2

A. Gajadhar and A. Guha, A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases, BioTechniques, vol.48, issue.2, pp.145-152, 2010.
DOI : 10.2144/000113354

D. Maurel, J. Kniazeff, G. Mathis, E. Trinquet, J. Pin et al., Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology, Analytical Biochemistry, vol.329, issue.2, pp.253-262, 2004.
DOI : 10.1016/j.ab.2004.02.013
URL : https://hal.archives-ouvertes.fr/hal-00318979

G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1038/256495a0

C. Larbouret, B. Robert, C. Bascoul-mollevi, F. Penault-llorca, A. Ho-pun-cheung et al., Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts, Annals of Oncology, vol.21, issue.1, pp.98-103, 2010.
DOI : 10.1093/annonc/mdp496
URL : https://hal.archives-ouvertes.fr/inserm-00431431

C. W. Adams, D. E. Allison, K. Flagella, L. Presta, J. Clarke et al., Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab, Cancer Immunology, Immunotherapy, vol.13, issue.Suppl 6, pp.717-727, 2006.
DOI : 10.1007/s00262-005-0058-x

M. C. Franklin, K. D. Carey, F. F. Vajdos, D. J. Leahy, A. M. De-vos et al., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell, vol.5, issue.4, pp.317-345, 2004.
DOI : 10.1016/S1535-6108(04)00083-2

D. B. Agus, R. W. Akita, W. D. Fox, G. D. Lewis, B. Higgins et al., Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, vol.2, issue.2, pp.127-164, 2002.
DOI : 10.1016/S1535-6108(02)00097-1

J. B. Hughes, C. Berger, M. S. Rødland, M. Hasmann, E. Stang et al., Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization, Molecular Cancer Therapeutics, vol.8, issue.7, pp.1885-1892, 2009.
DOI : 10.1158/1535-7163.MCT-09-0291

N. Takai, A. Jain, N. Kawamata, L. M. Popoviciu, J. W. Said et al., 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth, Cancer, vol.16, issue.12, pp.2701-2708, 2005.
DOI : 10.1002/cncr.21533

Z. Cai, G. Zhang, Z. Zhou, K. Bembas, J. A. Drebin et al., Differential binding patterns of monoclonal antibody 2C4 to the ErbB3???p185her2/neu and the EGFR???p185her2/neu complexes, Oncogene, vol.59, issue.27, pp.3870-3874, 2008.
DOI : 10.1038/339230a0

R. Nahta, M. Hung, and F. J. Esteva, The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells, Cancer Research, vol.64, issue.7, pp.2343-2346, 2004.
DOI : 10.1158/0008-5472.CAN-03-3856

M. Scaltriti, C. Verma, M. Guzman, J. Jimenez, J. L. Parra et al., Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity, Oncogene, vol.171, issue.6, pp.803-814, 2009.
DOI : 10.1107/S0907444993000423

T. T. Junttila, R. W. Akita, K. Parsons, C. Fields, L. Phillips et al., Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941, Cancer Cell, vol.15, issue.5, pp.429-440, 2009.
DOI : 10.1016/j.ccr.2009.03.020

A. H. Clayton, F. Walker, S. G. Orchard, C. Henderson, D. Fuchs et al., Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis, Journal of Biological Chemistry, vol.280, issue.34, pp.30392-30401, 2005.
DOI : 10.1074/jbc.M504770200

K. Furuuchi, A. Berezov, T. Kumagai, and M. I. Greene, Targeted Antireceptor Therapy with Monoclonal Antibodies Leads to the Formation of Inactivated Tetrameric Forms of ErbB Receptors, The Journal of Immunology, vol.178, issue.2, pp.1021-1030, 2007.
DOI : 10.4049/jimmunol.178.2.1021

E. M. Bublil, G. Pines, G. Patel, G. Fruhwirth, T. Ng et al., Kinase-mediated quasi-dimers of EGFR, The FASEB Journal, vol.24, issue.12, pp.4744-55, 2010.
DOI : 10.1096/fj.10-166199

P. Mullen, D. A. Cameron, M. Hasmann, J. F. Smyth, and S. P. Langdon, Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling, Molecular Cancer Therapeutics, vol.6, issue.1, pp.93-100, 2007.
DOI : 10.1158/1535-7163.MCT-06-0401

K. Kristjansdottir and D. Dizon, HER-dimerization inhibitors: evaluating pertuzumab in women's cancers, Expert Opinion on Biological Therapy, vol.8, issue.6, pp.243-250, 2010.
DOI : 10.1158/1541-7786.MCR-09-0101

A. Frolov, K. Schuller, C. D. Tzeng, E. E. Cannon, B. C. Ku et al., ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib, Cancer Biology & Therapy, vol.6, issue.4, pp.548-54, 2007.
DOI : 10.4161/cbt.6.4.3849
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.218.2330

C. L. Arteaga, T. T. Ramsey, L. K. Shawver, and C. A. Guyer, Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site, Journal of Biological Chemistry, vol.272, issue.37, pp.23247-23254, 1997.
DOI : 10.1074/jbc.272.37.23247

H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott et al., The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers: IMPLICATIONS FOR COMBINATION THERAPY WITH MONOCLONAL ANTIBODY 806, Journal of Biological Chemistry, vol.282, issue.5, pp.2840-2850, 2007.
DOI : 10.1074/jbc.M605136200

G. Heintz and S. , Bousquié for their technical assistance; C. Duperray for performing the selective cell sorting; M. Brissac and I. Ait-Arsa for help with the animal experiments; L. Le Cam for kindly providing retroviral vectors, and Roche for providing pertuzumab. This project was supported by ANR-07-RIB- 003